Effect of Dexmedetomidine on Postoperative Delirium After Awake Craniotomies

Condition(s) studied

Investigational drug(s) / intervention(s)

Dexmedetomidine: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.

0.9% saline: The 0.9% saline is administered with the same volume at the same speed as the other group.

Study summary

Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from 10% to 60%. Previous studies suggested that frontal approach and tumor located at the temporal lobe were independent risk factors for POD after supratentorial tumor resections. Therefore, patients undergoing awake craniotomies are high-risk populations for POD. A lot of trials show that dexmedetomidine might help to reduce the incidence of delirium in patients undergoing non-cardiac surgery. However, the impact of dexmedetomidine (DEX) on POD for patients undergoing awake craniotomies remains unclear. The purpose of this study was to investigate the effect of DEX on POD in patients undergoing awake craniotomies.

Eligibility

Primary outcome measure(s)

• The incidence of postoperative delirium. — postoperative 5 day.
  postoperative delirium is assessed by the combination of the Richmond Anxiety Scale (RASS) and the Confusion assessment method for intensive care unit (CAM-ICU) or the 3-minute diagnostic interview for CAM (3D-CAM) as applicable.

Trial sites (1)

More Beijing Tiantan Hospital trials in China

Other trials for the same condition